36 results
ARS
2023 FY
TARS
Tarsus Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
, our third-party supply chain providers, their facilities and XDEMVY used in our clinical trials or for commercial sale are required to be in compliance … and manufacture of XDEMVY to assess compliance with applicable regulations. Our failure, or the failure of our third-party providers and supply chain providers
8-K
EX-99.1
TARS
Tarsus Pharmaceuticals Inc
10 Aug 23
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
4:07pm
and supply chain or have other adverse effects on Tarsus’ business and operations; even if TP-03, TP-04, TP-05, or any other product candidate that Tarsus
8-K
EX-99.1
fs9vuc ec0un
9 May 23
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
4:07pm
ARS
i0757gt8 vf
26 Apr 23
Annual report to shareholders
4:08pm
8-K
EX-99.1
pd0k4 kjhp8
8 Nov 22
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
9:50pm
8-K
EX-99.1
7pkiovq6e1d6
11 Aug 22
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
4:09pm
8-K
EX-99.1
bw2 thae1ueiaorg
10 May 22
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements
4:16pm
8-K
4m2z2m6
3 May 22
Other Events
7:09am
FWP
x01q54zp
3 May 22
Free writing prospectus
6:16am
8-K
EX-99.1
i0pj62dqbs87m6
14 Mar 22
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements
4:14pm
8-K
EX-99.1
vl4 ma5lc6
9 Nov 21
Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements
4:06pm